Search

Displaying results 2691 - 2700 of 10000 in total
  1. Drug

    Venetoclax

    go.drugbank.com/drugs/DB11581
    ApprovedInvestigational

    Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. … Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells [A40022].

    Synonyms: 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide, 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
  2. Drug

    Clobetasone

    go.drugbank.com/drugs/DB13158
    Approved

    Clobetasone is a corticosteroid that is often employed topically as a treatment for a variety of conditions such as eczema, psoriasis, various forms of dermatitis, and also for certain ophthalmologic conditions

    Categories: Corticosteroids, Moderately Potent (Group II)
  3. Drug

    Iopanoic acid

    go.drugbank.com/drugs/DB08946
    ApprovedWithdrawn

    Iopanoic acid contains iodine and is useful as a contrast medium in cholecystography.

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Silver sulfadiazine

    go.drugbank.com/drugs/DB05245
    ApprovedInvestigationalVet approved

    Silver sulfadiazine is a sulfa derivative topical antibacterial used primarily on second- and third-degree burns.

  5. Drug

    Plasminogen

    go.drugbank.com/drugs/DB16701
    ApprovedInvestigational

    [L34635] In June 2021, the FDA approved a plasma-derived plasminogen (Ryplazim, human plasminogen-tvmh)[L34620] for the treatment of type 1 plasminogen deficiency (hypoplasminogenemia). … [L34615] It is the first and only FDA-approved treatment for this condition, which causes wood-like lesions to form on the mucous membranes of patients, providing an unmet medical need for patients with

  6. Drug

    Casirivimab

    go.drugbank.com/drugs/DB15941
    ApprovedInvestigational

    [L23524] In November 2021, the same indication was approved by the EMA. … Casirivimab is a monoclonal antibody combined with [Imdevimab] in Regeneron's antibody cocktail known as REGN-COV2 for the treatment of COVID-19.

  7. Drug

    Coagulation factor VIIa Recombinant Human

    go.drugbank.com/drugs/DB00036
    ApprovedInvestigational

    NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues. Cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.

    Categories: Increased Coagulation Factor IX Activity
  8. Drug

    Carphenazine

    go.drugbank.com/drugs/DB01038
    ApprovedWithdrawn

    Carphenazine is an antipsychotic drug, used in hospitalized patients in the management of chronic schizophrenic psychoses.

  9. Drug

    Ketazolam

    go.drugbank.com/drugs/DB01587
    ApprovedWithdrawn

    Ketazolam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant activity. Ketazolam is not approved in Canada or America.

  10. Drug

    Dichlorobenzyl alcohol

    go.drugbank.com/drugs/DB13269
    Approved

    [L1113] On the other hand, dichlorobenzyl alcohol is categorized by the FDA in the inactive ingredient for approved drug products.[L2773] … [A33047] Dichlorobenzyl alcohol is considered as an active ingredient found in several marketed OTC products by Health Canada which has categorized this agent as an anatomical therapeutic chemical.